65,437 trials
Antivirals/HIV
Primary: Average Area Under the Plasma Concentration-time Curve for 24 Hours (AUC24avg) for Rifabutin (RIB) — 1565; 2311 nanograms*hour /milliliters (ng*h/mL)
Stomach Neoplasms
Primary: Number of Participants With First-cycle Dose Limiting Toxicities (DLTs) — 1; 0 Participants
Endothelial Function · Lipids · Insulin Resistance
Primary: Flow-mediated Dilation (FMD) of the Brachial Artery — 0.03 Percentage — p=0.36
Invasive Pneumococcal Disease
Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…
Hemophilia B
Primary: Investigator Hemostatic Efficacy Assessment of Participants After 8 Hours Post Infusion — 1.70 Units on a scale
Erectile Dysfunction
Primary: Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12 — 15.5; 16.0; 7.3; 3.3 units on a scale — p=<0.001
Alpha 1-Antitrypsin Deficiency
Primary: Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level — 0.28 μM — p=0.0195
Gaucher Disease, Type 1
Primary: Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. — 1.624; 1.488 gram per deciliter (g/dl)
HIV Infections
Primary: Percentage of Participants Who Maintained Virologic Suppression (Less Than 50 RNA Cps/ml) — 100; 86 Percentage of Participants
Peritoneal Cancer · Ovarian Cancer · Neoplasms, Ovarian
Primary: Best Biochemical Response (Cancer Antigen [CA-125]) — 6; 25; 56; 3 percentage of participants
Age Related Macular Degeneration · Choroidal Neovascularization
Primary: Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye — 48.5; 38.9 Percentage of Participants
Hypertension
Primary: Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8 — -47.5; -36.9; -43.2 mmHg (millimeters of mercury) — p=<0.0001
Chronic Pain
Primary: Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15) — 0.88; 0.76 Units on scale — p=0.0004
Cervical Dystonia
Primary: Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units)…
Type 1 Diabetes
Primary: Pharmacokinetics of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients (Cmax) — 33.0 uU/mL